Antonio Ocejo, MD, discussed a multi-institutional analysis focusing on the clinical outcomes and tolerability of ipilimumab and nivolumab in patients with metastatic RCC.
Antonio Ocejo, MD
Antonio Ocejo, MD is a hematology/oncology fellow at Memorial Sloan Kettering Cancer Center.
Articles by Antonio Ocejo, MD